Pharmacogenetics of paraoxonases: a brief review
dc.contributor.author | Draganov, D. I. | en_US |
dc.contributor.author | La Du, Bert N. | en_US |
dc.date.accessioned | 2006-09-11T17:37:36Z | |
dc.date.available | 2006-09-11T17:37:36Z | |
dc.date.issued | 2004-01 | en_US |
dc.identifier.citation | Draganov, D. I.; La Du, B. N.; (2004). "Pharmacogenetics of paraoxonases: a brief review." Naunyn-Schmiedeberg's Archives of Pharmacology 369(1): 78-88. <http://hdl.handle.net/2027.42/46312> | en_US |
dc.identifier.issn | 1432-1912 | en_US |
dc.identifier.issn | 0028-1298 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46312 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14579013&dopt=citation | en_US |
dc.description.abstract | The human paraoxonase (PON) gene family consists of three members, PON1 , PON2 , and PON3 , aligned next to each other on chromosome 7. By far the most-studied member of the family is the serum paraoxonase 1 (PON1), a high-density lipoprotein-associated esterase/lactonase. Early research focused on its capability to hydrolyze toxic organophosphates, and its name derives from one of its most commonly used in vitro substrates, paraoxon. Studies in the last 2 decades have demonstrated PON1’s ability to protect against atherosclerosis by hydrolyzing specific derivatives of oxidized cholesterol and/or phospholipids in oxidized low-density lipoprotein and in atherosclerotic lesions. Levels and genetic variability of PON1 influence sensitivity to specific insecticides and nerve agents, as well as the risk of cardiovascular disease. More recently, the other two members of the PON family, PON2 and PON3, have also been shown to have antioxidant properties. A major goal in present research on the paraoxonases is to identify their natural substrates and to elucidate the mechanism(s) of their catalytic activities. | en_US |
dc.format.extent | 389513 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Polymorphism | en_US |
dc.subject.other | Pharmacogenetics | en_US |
dc.subject.other | Arylesterase | en_US |
dc.subject.other | LifeSciences | en_US |
dc.subject.other | Lactonase | en_US |
dc.title | Pharmacogenetics of paraoxonases: a brief review | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, MSRB 3, Room 1301, University of Michigan, Ann Arbor, MI 48109-0632, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, MSRB 3, Room 1301, University of Michigan, Ann Arbor, MI 48109-0632, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 14579013 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46312/1/210_2003_Article_833.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00210-003-0833-1 | en_US |
dc.identifier.source | Naunyn-Schmiedeberg's Archives of Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.